VTRS vs. TAK, ALNY, TEVA, GMAB, RPRX, BMRN, BGNE, UTHR, SRPT, and RDY
Should you be buying Viatris stock or one of its competitors? The main competitors of Viatris include Takeda Pharmaceutical (TAK), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), BeiGene (BGNE), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical preparations" industry.
Takeda Pharmaceutical (NYSE:TAK) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability, community ranking and risk.
In the previous week, Viatris had 4 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 5 mentions for Viatris and 1 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.48 beat Viatris' score of 0.47 indicating that Viatris is being referred to more favorably in the news media.
Takeda Pharmaceutical has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.
9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Takeda Pharmaceutical received 78 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 56.82% of users gave Takeda Pharmaceutical an outperform vote while only 36.67% of users gave Viatris an outperform vote.
Takeda Pharmaceutical has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Takeda Pharmaceutical has a net margin of 6.18% compared to Takeda Pharmaceutical's net margin of -0.37%. Takeda Pharmaceutical's return on equity of 16.63% beat Viatris' return on equity.
Takeda Pharmaceutical presently has a consensus price target of $14.00, suggesting a potential upside of 1.67%. Viatris has a consensus price target of $12.33, suggesting a potential upside of 2.10%. Given Takeda Pharmaceutical's higher possible upside, analysts plainly believe Viatris is more favorable than Takeda Pharmaceutical.
Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 3.5%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 4.0%. Takeda Pharmaceutical pays out 87.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Viatris pays out -800.0% of its earnings in the form of a dividend. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.
Summary
Viatris beats Takeda Pharmaceutical on 11 of the 19 factors compared between the two stocks.
Get Viatris News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
Free VTRS Stock Alerts